Alzheimer's disease is characterized by a progressive neuronal degeneration in several brain regions leading to severe cognitive deficits.
The diagnosis of Alzheimer's disease is based on the presence of protein deposits inside and outside the neurons: neurofibrillary tangles and senile plaques, respectively.
To date, the main objective of worldwide research has been to develop therapies to prevent or reduce the formation of these deposits.
These investigations have been unsuccessful, probably because they are directed to the later stages of the process, where degeneration is irreversible.
These investigations have been unsuccessful, probably because they are directed to the later stages of the process, where degeneration is irreversible.
Some figures…
+ 47 million people currently affected.
+ € 711 billion of global spending.
+ 104 million patients planned for 2050.
It is crucial to find new therapeutic targets associated with the onset of the disease. In this sense, the line of research undertaken by Tetraneuron is completely disruptive and different from those carried out to date.
